No amount of PR will do any good, until the street see's some sales numbers. The PR has to go towards Md's and I'm confident MGI is out there relating the information. This is a class effect and both drugs sales should continue to grow. PHRM is going to keep up the pressure that they've got the only data. That means we will not get our footing until ASH and the underlying information gets released. This is how it works in biotech.